Skip to main content

ADVERTISEMENT

disease progression

Research Reports
11/27/2017
Editor's Note: This article was updated for minor editorial additions and formatting changes, per request of the authors. Abstract: In order to identify drivers of chronic kidney disease (CKD) stage progression and...
Editor's Note: This article was updated for minor editorial additions and formatting changes, per request of the authors. Abstract: In order to identify drivers of chronic kidney disease (CKD) stage progression and...
...
11/27/2017
Journal of Clinical Pathways
Research in Review
01/08/2016
JCP Editors
First-line treatment with erlotinib for epidermal growth factor receptor (EGFR) mutation–positive non-small cell lung cancer (NSCLC) patients may have benefits even after disease progresses, a new study...
First-line treatment with erlotinib for epidermal growth factor receptor (EGFR) mutation–positive non-small cell lung cancer (NSCLC) patients may have benefits even after disease progresses, a new study...
...
01/08/2016
Journal of Clinical Pathways